[
    [
        {
            "time": "2021-01-27",
            "original_text": "万盛股份连发股权转让与定增方案 将易主“复星系”郭广昌 资产异常",
            "features": {
                "keywords": [
                    "万盛股份",
                    "股权转让",
                    "定增方案",
                    "复星系",
                    "郭广昌"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "化工"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "万盛股份连发股权转让与定增方案 将易主“复星系”郭广昌 资产异常",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-01-27",
            "original_text": "格隆汇港股聚焦(01.27)︱建业新生活年度纯利预增逾八成；药明生物年度净利预增超65%",
            "features": {
                "keywords": [
                    "建业新生活",
                    "药明生物",
                    "纯利预增",
                    "净利预增"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "房地产服务",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(01.27)︱建业新生活年度纯利预增逾八成；药明生物年度净利预增超65%",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-01-27",
            "original_text": "智通港股公告精选|(1.27) 药明生物预期2020年度股东应占利润同比增65%以上",
            "features": {
                "keywords": [
                    "药明生物",
                    "股东应占利润",
                    "同比增65%"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智通港股公告精选|(1.27) 药明生物预期2020年度股东应占利润同比增65%以上",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-01-27",
            "original_text": "复星首批新冠疫苗2月抵港 争取尽快在内地应用",
            "features": {
                "keywords": [
                    "复星",
                    "新冠疫苗",
                    "抵港",
                    "内地应用"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星首批新冠疫苗2月抵港 争取尽快在内地应用",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-01-27",
            "original_text": "复星医药(02196)拟发行2021年公司债券(第一期)",
            "features": {
                "keywords": [
                    "复星医药",
                    "公司债券",
                    "发行"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(02196)拟发行2021年公司债券(第一期)",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-01-27",
            "original_text": "上海复星高科技(集团)增持复星医药(02196)265万股，每股作价38.23港元",
            "features": {
                "keywords": [
                    "上海复星高科技",
                    "复星医药",
                    "增持",
                    "每股作价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "上海复星高科技(集团)增持复星医药(02196)265万股，每股作价38.23港元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-01-27",
            "original_text": "复星医药：目前公司已启动2020年相关减值测试工作",
            "features": {
                "keywords": [
                    "复星医药",
                    "减值测试"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药：目前公司已启动2020年相关减值测试工作",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]